Volumes have soared almost 63 per cent in the last seven trading session. The price of the Advik Labs scrip has moved up from Rs 19.25 on September 25 to Rs 25.45.
The company has been in the limelight recently because of interest shown by Max Medical, UK, to acquire equity stake in the company up to $10 million at a price of Rs 35 per share.
Advik has entered the biotech product market and unveiled life recombinant DNA products such as drugs vaccines & diagnostics.
The company is in the process of negotiating with European & American biotech companies for developing biotech products for them in India.
The company has bagged an export order worth Rs 20 crore from Qmedic & Wayne LLC, UAE, for supply of generic drugs and multi-vitamins.
Advik Laboratories has also recently entered into technical collaboration with PFC Pharma Focus, Switzerland, engaged into the manufacture of pharmaceuticals tablets, capsules & dry syrups equipped with modern equipment of GMP standards will acquire 12 acres of land and a readymade Biotech unit with around 20,000 sq. feet built up facilities at Pune.
The company is planning to tie-up with UK based Integral Pharma Services and open offices in Brazil, Latin America, as per Federation of Indian Exports
